Squarepoint
MRNS

Squarepoint’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Squarepoint’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-74,223
Closed -$131K – 5625
2024
Q3 		$131K Sell
74,223
-101,512
-58% -$142K ﹤0.01% 3811
2024
Q2 		$206K Buy
+175,735
New +$440K ﹤0.01% 3642
2021
Q2 		– Sell
-14,657
Closed -$227K – 3819
2021
Q1 		$227K Sell
14,657
-17,639
-55% -$255K ﹤0.01% 2626
2020
Q4 		$394K Buy
32,296
+19,822
+159% +$276K ﹤0.01% 2001
2020
Q3 		$160K Buy
+12,474
New +$108K ﹤0.01% 2174
2020
Q2 		– Sell
-9,399
Closed -$76K – 2585
2020
Q1 		$76K Buy
+9,399
New +$81.4K ﹤0.01% 1682
2019
Q1 		– Sell
-6,019
Closed -$69K – 2506
2018
Q4 		$69K Buy
+6,019
New +$122K ﹤0.01% 1829
2018
Q1 		– Sell
-4,845
Closed -$158K – 2246
2017
Q4 		$158K Buy
+4,845
New +$131K ﹤0.01% 1865
2017
Q1 		– Sell
-3,250
Closed -$13K – 1977
2016
Q4 		$13K Buy
+3,250
New +$15.1K ﹤0.01% 1730

Other funds holding MRNS

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint's MRNS Position: Q4 2024 in Review

Squarepoint sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q4 2024, closing a stake of 74,223 shares — an estimated $131K sold.

Squarepoint first reported a position in MRNS in Q4 2016 and held it in 9 quarters. The position peaked at $394K in Q4 2020. 53 funds tracked by Wall St. Rank hold MRNS as of Q4 2024.

  • Squarepoint reported no remaining Marinus Pharmaceuticals, Inc position as of Q4 2024 after selling out during the quarter.
  • Squarepoint sold 74,223 Marinus Pharmaceuticals, Inc shares in Q4 2024, an estimated $131K.
  • Squarepoint first reported a position in Marinus Pharmaceuticals, Inc in Q4 2016 and held it in 9 quarters.
  • Squarepoint's Marinus Pharmaceuticals, Inc position peaked at $394K in Q4 2020.
  • 53 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q4 2024.

Based on Squarepoint's 13F filing for Q4 2024, filed 14 Feb 2025.